
Oncotarget
Intraventricular Immunovirotherapy; A Translational Step Forward
Jan 26, 2023
Researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman discuss Intraventricular Immunovirotherapy in cancer treatment using engineered type 1 herpes simplex virus. They highlight its efficacy in recent clinical trials for high-grade glioma and potential for targeting intractable diseases like disseminated medulloblastoma. The importance of Intraventricular Administration for targeted immunovirotherapy is emphasized.
02:44
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Intraventricular Immunovirotherapy shows safety and efficacy in recent trials for high-grade glioma treatment.
- Intraventricular Administration of OHV, specifically with G207, demonstrates potential for intractable diseases treatment.
Deep dives
Intraventricular Immunovirotherapy for Glioma Treatment
Researchers discuss the use of Intraventricular Immunovirotherapy (IVT) with an Intra Temoral Engineered Type 1 Herpes Simplex Virus (HSV) for treating pediatric and adult high-grade glioma. IVT has shown safety and efficacy in recent trials, particularly with Oncolytic Herpes Simplex Virus Type 1 (OHV). A recent preclinical study has addressed toxicity concerns, paving the way for clinical translation of IVT with promising therapeutic benefits in disseminated medulloblastoma models.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.